Xencor Reports Third-Quarter 2026 Financial Results
Xencor updated results for XmAb819 in advanced clear cell renal cell carcinoma.
Story updates
09:15:01 PM UTC
SquawkNews
Xencor reported third-quarter 2026 revenue of $116.52M, compared with $21M a year earlier, and net income of $39.44M versus a prior-year loss of $6.03M. Results included revenue from the Alexion settlement and partner milestones.Financial Highlights¹ Reported as “Revenue”. ² Reported as “Net income…